A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink.

International Journal of Chronic Obstructive Pulmonary Disease
Cristina RebordosaElena Rivero-Ferrer

Abstract

The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A Post-Authorisation Safety Study (PASS) was initiated to assess potential cardiovascular safety concerns for aclidinium. To estimate the adjusted incidence rate ratio (IRR) for hospitalisation for heart failure in patients with COPD who were new users of aclidinium, tiotropium, other LAMA, long-acting beta-agonists/inhaled corticosteroids (LABA/ICS), and LAMA/LABA were compared with initiators of LABA. This population-based cohort study included patients with COPD aged ≥40 years initiating COPD medications in the Clinical Practice Research Datalink (CPRD) GOLD in the United Kingdom from 2012 to 2017. Medications were identified via general practice prescriptions. The first-ever hospitalisations for heart failure were identified in the Hospital Episode Statistics, and general practitioner records from the CPRD. Poisson regression models were used to estimate the IRR for hospitalisation for heart failure in users of COPD medications versus LABA, adjusting for clinically relevant covariates. The study included 4350 new users of aclidinium, 23,405 of tiotropium, 6977 of o...Continue Reading

References

May 14, 2003·Pharmacotherapy·Susan S JickHershel Jick
Nov 4, 2004·American Heart Journal·David H AuUNKNOWN ACQUIP Investigators
Mar 8, 2007·European Journal of Epidemiology·Cynthia de LuiseHenrik T Sørensen
Nov 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michele JaraSteven Kesten
May 21, 2008·International Journal of Chronic Obstructive Pulmonary Disease·Christine MacieNicholas Anthonisen
Apr 14, 2009·Chest·Sarika S OgaleSean D Sullivan
Dec 22, 2009·Chest·Gavin C DonaldsonJadwiga A Wedzicha
Jan 19, 2010·British Journal of Clinical Pharmacology·Emily HerrettAndrew J Hall
Apr 2, 2010·European Journal of Heart Failure·Nathaniel M HawkinsUNKNOWN CHARM Investigators and Committees
Nov 5, 2011·Pulmonary Pharmacology & Therapeutics·K M C VerhammeM C J M Sturkenboom
Jan 25, 2012·Pharmacoepidemiology and Drug Safety·Jane S SaczynskiJerry H Gurwitz
Jun 8, 2015·International Journal of Epidemiology·Emily HerrettLiam Smeeth
May 26, 2017·The European Respiratory Journal·Samy SuissaPierre Ernst
Feb 15, 2018·American Journal of Respiratory and Critical Care Medicine·Ken M KunisakiUNKNOWN SUMMIT Investigators
May 10, 2018·Pharmacoepidemiology and Drug Safety·Cristina RebordosaJordi Castellsague
Sep 14, 2018·The European Respiratory Journal·Jørgen VestboDave Singh
Mar 13, 2020·American Journal of Respiratory and Critical Care Medicine·David A LipsonFernando J Martinez
Dec 10, 2020·ERJ Open Research·Stefan Andreas, Christian Taube

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.